MedPath

Alebund Pharmaceuticals Secures Nearly RMB 200 Million in Pre-C Round Financing

Alebund Pharmaceuticals, a leader in innovative kidney disease treatments, has successfully closed a Pre-C round of financing, raising nearly RMB 200 million. The funds will bolster the company's R&D pipeline, which includes three Class I innovative drugs in various stages of clinical development, with additional products expected to enter clinical testing by 2024.

Alebund Pharmaceuticals, recognized for its pioneering work in developing innovative treatments for kidney disease, has announced the closure of its Pre-C round of financing, securing nearly RMB 200 million. This significant financial boost is earmarked for advancing the company's R&D pipeline, which is currently focused on three Class I innovative drugs undergoing Phase I, II, and III clinical developments.
With a team rich in renal R&D experience, Alebund is committed to enhancing its portfolio to benefit patients globally. The company anticipates that 1-2 in-house developed products will enter clinical testing by 2024, marking a significant milestone in its mission to address kidney disease through innovative medical solutions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Eledon Pharmaceuticals' Tegoprubart Shows Promise in Transplantation Therapies

Eledon Pharmaceuticals completed Phase 2 BESTOW trial enrollment for tegoprubart in kidney transplantation, with topline results expected in Q4 2025.
Updated Phase 1b data supports tegoprubart's safety and tolerability in preventing kidney transplant rejection, showing stable eGFR in patients.

Walden Biosciences Advances Kidney Disease Therapies with WAL0921 and WAL0623

Walden Biosciences has fully enrolled the second cohort in its Phase 2 basket study of WAL0921 for chronic kidney disease, targeting diabetic nephropathy.
The company plans to initiate a cohort in early 2025 focusing on rare glomerular kidney diseases, including FSGS, TR-MCD, IgAN, and PMN.

AnaCardio Raises SEK 205 Million and Reports Positive Phase 1b Data of AC01

AnaCardio, a portfolio company of Karolinska Development, has successfully raised SEK 205 million and announced positive results from its Phase 1b clinical trial of AC01. Karolinska Development, a Nordic life sciences investment company, focuses on advancing medical innovations into commercial products that aim to improve patients' lives while offering attractive returns to shareholders.

Alebund Pharmaceuticals Completes Series C Financing of RMB 550 Million

Alebund Pharmaceuticals, a biopharmaceutical company specializing in innovative therapies for renal diseases, has successfully completed a Series C financing round of RMB 550 million. This funding will support the development and commercialization of its renal disease pipelines and accelerate clinical-stage programs.

ARIAD Pharmaceuticals Accelerates Ponatinib to Market

ARIAD Pharmaceuticals is pushing forward with the development and approval of its new cancer drug, Ponatinib, aimed at treating resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. With promising clinical trial results and a rolling submission for New Drug Application completed, ARIAD seeks accelerated approval from the FDA and EMA, projecting significant market potential.

Rapport Therapeutics Advances RAP-219 Clinical Trials for CNS Disorders

Rapport Therapeutics is progressing with Phase 2a trial of RAP-219 in focal epilepsy, with topline data expected in mid-2025.
Multiple Ascending Dose (MAD-2) and PET trials of RAP-219 are ongoing, with topline results anticipated in Q1 2025.

Upstream Bio Secures $200 Million in Series B Funding to Advance UPB-101 for Inflammatory Diseases

Upstream Bio has completed a $200 million Series B financing round to support the clinical development of UPB-101, a monoclonal antibody targeting the TSLP receptor.
The funding will facilitate Phase 2 clinical trials of UPB-101 in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), along with translational and manufacturing activities.

LB Pharmaceuticals Advances Schizophrenia Treatment with LB-102

LB Pharmaceuticals is making strides in the treatment of schizophrenia with its novel drug candidate, LB-102. The company has successfully completed a Phase 1 clinical trial, demonstrating the drug's safety and tolerability in healthy volunteers. With a unique mechanism targeting dopamine D2/3 and 5-HT7 receptors, LB-102 aims to offer improved efficacy and safety over existing treatments. The company plans to advance LB-102 into Phase 2 trials, focusing on its potential to address the significant unmet needs in schizophrenia treatment.

I-Mab Announces 2022 Financial Results and Pipeline Updates, Highlighting Key Clinical Milestones

I-Mab achieved thirteen key clinical milestones in 2022, including positive data readouts for lemzoparlimab, uliledlimab, and givastomig, alongside progress in eftansomatropin alfa and felzartamab.
The company is strategically prioritizing its pipeline, focusing on key clinical assets and streamlining operations, which has significantly reduced the cash burn rate.

Reference News

[1]
Alebund Pharmaceuticals Closes Nearly RMB 200 Million P...
lavfund.com · Apr 12, 2023

Alebund, a leader in kidney disease treatments, focuses on advancing its R&D pipeline with funds from recent financing. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy